Reimbursement For Manufacturing Of Commercial Supplies — Revenue
Regeneron Pharmaceuticals Reimbursement For Manufacturing Of Commercial Supplies — Revenue decreased by 0.1% to $154.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.5%, from $165.00M to $154.30M. Over 4 years (FY 2021 to FY 2025), Reimbursement For Manufacturing Of Commercial Supplies — Revenue shows an upward trend with a 7.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests higher production volume for partners or expanded manufacturing service agreements, while a decrease may indicate a shift in manufacturing responsibilities or lower demand for partner-marketed products.
Detailed definition
This metric represents revenue generated from providing contract manufacturing services for commercial-stage pharmaceuti...
Peer comparison
Comparable to contract manufacturing revenue or service-based collaboration income found in other biopharmaceutical companies with significant R&D and manufacturing partnerships.
regn_segment_reimbursement_for_manufacturing_of_commercial_supplies_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $110.90M | $144.70M | $127.60M | $160.80M | $145.50M | $160.50M | $166.90M | $161.90M | $192.60M | $151.50M | $107.00M | $105.80M | $157.30M | $175.10M | $169.70M | $165.00M | $161.50M | $161.50M | $154.40M | $154.30M |
| QoQ Change | — | +30.5% | -11.8% | +26.0% | -9.5% | +10.3% | +4.0% | -3.0% | +19.0% | -21.3% | -29.4% | -1.1% | +48.7% | +11.3% | -3.1% | -2.8% | -2.1% | +0.0% | -4.4% | -0.1% |
| YoY Change | — | — | — | — | +31.2% | +10.9% | +30.8% | +0.7% | +32.4% | -5.6% | -35.9% | -34.7% | -18.3% | +15.6% | +58.6% | +56.0% | +2.7% | -7.8% | -9.0% | -6.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Regeneron Pharmaceuticals (REGN) reported reimbursement for manufacturing of commercial supplies — revenue of $154.30M in Q1 2026.
- How has Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue changed year-over-year?
- Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue decreased by 6.5% year-over-year, from $165.00M to $154.30M.
- What is the long-term trend for Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's reimbursement for manufacturing of commercial supplies — revenue has grown at a 7.1% compound annual growth rate (CAGR), from $488.80M to $642.40M.
- What does reimbursement for manufacturing of commercial supplies — revenue mean?
- Revenue earned from manufacturing pharmaceutical products on behalf of collaboration partners.